

# ChemComm

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

*Accepted Manuscripts* are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

## COMMUNICATION

## Heterologous Expression of Highly Reducing Polyketide Synthase Involved in Betaenone Biosynthesis

Cite this: DOI: 10.1039/x0xx00000x

Received 00th January 2012,  
Accepted 00th January 2012Takahiro Ugai,<sup>a</sup> Atsushi Minami,<sup>a</sup> Ryuya Fujii,<sup>a</sup> Mizuki Tanaka,<sup>b</sup> Hiroki Oguri,<sup>a</sup>  
Katsuya Gomi,<sup>b</sup> and Hideaki Oikawa<sup>a</sup>

DOI: 10.1039/x0xx00000x


www.rsc.org/

**A unique highly reducing polyketide synthase (HR-PKS) with a reductase domain was identified in a betaenone biosynthetic gene cluster. Successful heterologous expression and characterization of the HR-PKS and trans-acting enoyl reductase (ER) provide insights into the core structure formation with a decalin scaffold and allow reconstitution of the betaenone biosynthetic machinery.**

Fungal polyketides are structurally diverse secondary metabolites exhibiting a wide range of biological activities.<sup>1</sup> Representative examples are the Ras farnesylation inhibitor phomoidride<sup>2</sup> and the cholesterol-lowering agents lovastatin<sup>3</sup> and zaragozic acid.<sup>4</sup> Assembly of the carbon skeleta is catalyzed by type I polyketide synthases (PKSs).<sup>5,6</sup> Unlike the bacterial multi-modular type I PKSs, fungal type I PKSs have a single modular architecture and iteratively use a single set of active sites through multiple catalytic cycles.<sup>5,6</sup> According to the domain organization, fungal type I PKSs are classified into nonreducing (NR), partially reducing (PR), and highly reducing (HR) PKSs. Among them, HR-PKSs contain three fundamental chain extension domains,  $\beta$ -ketoacyl synthase (KS), acyltransferase (AT), and acyl carrier protein (ACP), and additional

$\beta$ -keto-processing domains, ketoreductase (KR), dehydratase (DH), and enoyl reductase (ER). Branched methyl groups on the polyketide chain are introduced by the catalysis of methyltransferase (MT). Intriguingly, most HR-PKSs lack a chain-release domain, and limited information is available for the chain-release mechanism. This is one of the bottlenecks in the analysis of the function of HR-PKSs and the reconstitution of the biosynthetic machinery.

Betaenones A-C (**1-3**) are phytotoxic polyketides isolated from *Phoma betae Fr.*, the causal fungus of leaf spot disease in sugar beets (Scheme 1).<sup>7</sup> Among betaenones, **3** exhibits the highest phytotoxic activity on wilting of the host plant.<sup>7</sup> The unique structural feature of **1** is the highly substituted tricycle[6.2.2.0]dodecane skeleton derived from an intramolecular aldol reaction of **3**, which harbors a  $\beta$ -ketoaldehyde side chain attached to a decalin scaffold. Feeding experiments with isotopically labeled precursors suggested that the carbon skeleton is constructed in a common polyketide pathway catalyzed by HR-PKS.<sup>8</sup> Treatment with a cytochrome P450 inhibitor, ancymidol, enabled us to isolate probetaenone I (**4**).<sup>9</sup> Incorporation of isotopically labeled **4** into **2** showed that **4** is a biosynthetic intermediate in betaenone B biosynthesis.<sup>10</sup> Taken together with these results, the biosynthetic pathway of **1** was proposed as shown in Scheme 1. Of particular



**Scheme 1.** Proposed biosynthetic pathway of betaenone A. Methyl groups derived from SAM are marked with an asterisk.

interest in the skeletal construction are the plausible direct reductive cleavage of the linear polyketide chain to give the  $\beta$ -ketoaldehyde moiety found in dehydroprobetaneone I (**5**), a putative biosynthetic intermediate in the production of **1**, and [4+2] cycloaddition to construct the *trans*-decalin skeleton. In this paper, we report the identification of a betaenone biosynthetic gene cluster and the heterologous expression of HR-PKS in *Aspergillus oryzae* to elucidate the characteristic chain-release mechanism and decalin scaffold formation. The successful functional characterization of HR-PKS allows us to reconstitute the biosynthetic machinery of betaenone B.

Isolation of probetaenone I and betaenone C as biosynthetic intermediates showed an involvement of the reductase (R) domain of HR-PKS, a typical domain that catalyzes the reductive release of the aromatic polyketide chain in the NR-PKS system, and oxidative modification enzymes. The draft genome sequence of *P. betae* revealed that the genome contains six HR-PKS genes, of which two HR-PKSs have a terminal reductase (R) domain. Of these two HR-PKS-encoding open reading frames, we assumed that the HR-PKS gene in the gene cluster also containing a cytochrome P450 gene is responsible for betaenone biosynthesis. This putative biosynthetic gene cluster (*bet*) encoded four genes as shown in Figure 1 and Table S1. Bet1 displays similarity to HR-PKS and is composed in a KS-AT-DH-MT-ER<sup>0</sup>-KR-ACP-R domain order, which is identical in domain organization to that of typical HR-PKSs, except for the C-terminal R domain and inactive ER domain (see below). Bet2 is a cytochrome P450, a typical oxidation enzyme that activates an inert C-H bond. Bet3 displays similarity to ER and might act as a functional alternative to the inactive ER domain of Bet1. Bet4 exhibits homology to short-chain dehydrogenase, possibly involved in a modification reaction (Table S1). Two genes, *orf1* and *orf2*, are located upstream of *bet4* and encode a putative FAD-dependent oxidase and dehydrogenase, respectively (Table S1).

To characterize the function of individual biosynthetic enzymes, we applied a heterologous expression system in *A. oryzae*, a promising method to elucidate biosynthetic machinery of fungal metabolites. Representative examples are found in the total biosynthesis of tenellin,<sup>11</sup> aphidicolin,<sup>12</sup> paxilline,<sup>13</sup> aspyridone,<sup>14</sup> aflatrem,<sup>15</sup> and anditomin (11 + 1 genes).<sup>16</sup> For skeletal construction of **1** in *A. oryzae*, *bet1* and *bet3* genes were subcloned into fungal expression vectors, pUARA2 (*argB* marker) and pUSA2 (*sC* marker),<sup>15</sup> to construct pUARA2-*bet1* and pUSA2-*bet3*, which were then introduced into *A. oryzae* NSAR1 to construct both a *bet1* single transformant and *bet1/3* double transformant (Figure S1(A)). The metabolite profile of each transformant cultured on solid




**Figure 1.** Genetic organization of the betaenone biosynthetic gene cluster.

medium was examined by LC-MS (Figure 2 (A)-(C)). One new metabolite (188 mg per kg of rice) was observed only in the extracts from *bet1/3* transformants (Figure 2 (C), Figure S2 (A)). Based on HR-MS data ( $m/z$  319.2682 [M+H]<sup>+</sup>), the molecular formula of the new metabolite was determined as C<sub>21</sub>H<sub>34</sub>O<sub>2</sub>, which is consistent with that of dehydroprobetaneone I (**5**). In addition, the <sup>1</sup>H-NMR spectrum of the new metabolite was similar to that of **4** except for characteristic signals of an enol form of the  $\beta$ -ketoaldehyde moiety at 15.5 (s), 7.39 (m), and 5.41 (d,  $J = 4.9$  Hz) ppm (See supporting information), suggesting production of **5** in the *bet1/3* transformant. Treatment of the metabolite with NaBH<sub>4</sub> resulted in reduction of the aldehyde moiety (Scheme S1). The <sup>1</sup>H-NMR spectrum of the product completely agreed with that of **4**,<sup>9</sup> allowing us to determine the structure of the observed metabolite as **5**. These results showed that the collaborative action of Bet1 and Bet3 plays a key role in the skeletal construction of **5** in betaenone biosynthesis.

After identifying the observed metabolite of the *bet1/3* transformant, we then focused on the subsequent reduction step. Since Bet4, which is homologous to short-chain dehydrogenase, is likely to be involved in the reduction of **5**, *bet4* was subcloned into the *NheI* site of the pAdeA2 vector (*adeA* marker; Figure S3) to construct pAdeA2-*bet4*. The *bet1/3* double transformant was then transformed with pAdeA2-*bet4* to create a *bet1/3/4* transformant (Figure S1 (B)). The triple transformant produced a new metabolite (17.4 mg/kg; Figure 2 (D), Figure S2 (B)) having a retention time and MS spectrum identical to those of authentic **4**,<sup>17</sup> demonstrating that Bet4 catalyzes reduction of **5** to **4** in betaenone biosynthesis.

Next, we turned our attention to the oxidative modification of the decalin scaffold. Plausible candidate *bet2*, a cytochrome P450 gene, was subcloned into the *NheI* site of the pAdeA2 vector to construct pAdeA2-*bet2*, which was used for transformation of the *bet1/3* double transformant, creating a *bet1/2/3* transformant (Figure S1 (C)). LC-MS analysis of the extracts showed production of a new metabolite (153 mg/kg) (Figure 2 (E), Figure S2 (C)). The retention time and MS spectrum were identical to those of authentic betaenone B (Figure S2 (D)), thus revealing that this new metabolite **2** is betaenone B. The structure of **2** was further confirmed by <sup>1</sup>H-NMR analysis (See supporting information). These results suggested that Bet2 catalyzes multistep oxidations from **5** to **3** and that an enzyme existed in *A. oryzae* unexpectedly mediates the reduction of the  $\beta$ -ketoaldehyde moiety of **3** to give **2**. Introduction of *orf1* or *orf2* in the *bet1/2/3* transformant did not give a new metabolite, suggesting that functionally unassigned genes adjacent to the *bet* gene cluster can be involved in the aldol reaction of **3** to afford **1**. In the present transformation studies, the frequency rate (the ratio of functionally active clones to obtained clones) is summarized as follows: *bet1/3* (2/5), *bet1/3/4* (4/6), and *bet1/2/3* (5/5). Notably, in all cases, we obtained the functionally active clone in a single transformation, demonstrating that heterologous expression in *A. oryzae* is a reliable method to characterize the function of biosynthetic genes.

Currently, to our knowledge, polyketide chain-release mechanisms of HR-PKSs are mainly classified into the following three mechanisms (Table S2): 1) spontaneous cleavage accompanying pyrone formation found in solanapyrone<sup>18</sup> and




**Figure 2.** LC-MS profiles of metabolites produced by transformants. A) *A. oryzae* NSAR1. B) *bet1* transformant. C) *bet1/3* transformant. D) *bet1/3/4* transformant. E) *bet1/2/3* transformant.


alternapyrone<sup>19</sup> biosynthesis, 2) polyketide chain transfer from HR-PKS to the starter unit:ACP transacylase (SAT) domain of NR-PKS in several HR-PKS/NR-PKS systems,<sup>5, 6</sup> and 3) enzymatic cleavage of polyketide chain catalyzed by thioesterase and acyltransferase reported in lovastatin biosynthesis.<sup>20, 21</sup> Intriguingly, in these cases, no inherent chain-release domain is installed on the HR-PKS. By contrast, the production of **5** in the *bet1/3* transformant indicated that the C-terminal R domain of Bet1 catalyzes reductive release of the polyketide chain, differentiating the function of Bet1 from that of other HR-PKSs. To reveal the function of the conserved SYK catalytic triad (S2705/Y2737/K2741)<sup>22</sup> found in Bet1-R domain (Figure S4), mutational analysis was then conducted. In contrast to the *bet1/3* transformant, no detectable level of **5** was produced by double transformants with a *bet1* mutant gene (S2705A, Y2737F, and K2741A), suggesting the importance of the catalytic triad in reductive cleavage of the polyketide chain (Figure S5 (D)-(F)). Unfortunately, the chemical release of the PKS-bound mature polyketide chain by alkaline treatment<sup>23</sup> failed.

A previous synthetic study of betaenone<sup>17</sup> in which linear triene gave modified probetaenone I as a sole product suggested that existing stereogenic centers of the triene precursor control diastereoselectivity, and the role of enzyme is acceleration of the reaction rate in the [4+2] cycloaddition possibly by stabilizing the transition state and activating dienophile. Currently, enzymatic decalin scaffold formation by [4+2] cycloaddition is firmly established in the biosynthesis of the two fungal polyketides, solanapyrone<sup>18, 24</sup> and lovastatin<sup>23</sup> (Scheme 2 (A), (B)). In the latter case, the HR-PKS LovB catalyzes a Diels-Alder reaction of intermediate I during the chain extension process (Scheme 2 (B)). Our experimental evidence that the *bet1/3* transformant gave a [4+2] cycloadduct suggested that the HR-PKS Bet1 may mediate a Diels-Alder reaction of intermediate II-1 followed by additional chain extension of intermediate II-2 to afford the core structure of **5** (Scheme 2 (C); pathway 1). However, the unusual observation that only the terminal carbonyl group of **5** was reduced by the small reducing agent NaBH<sub>4</sub> questioned this scenario. To examine the reactivity of the carbonyl group in **5**, we performed a conformational search using MacroModel. All low-energy conformers obtained (<8 kJ/mol) were essentially the same as a decalin moiety and just differed in the orientation of secondary butyl and  $\beta$ -hydroxyenone groups (Figure 3 and Figure S6). This result was supported by <sup>1</sup>H-NMR data. The highly congested carbonyl group in the conformers of **5** and probably in intermediate II-2 likely shows resistance to nucleophilic attack of NaBH<sub>4</sub> and enolate from the malonyl unit, respectively. In the previous report, we pointed out that prosolanapyrone synthase (PSS) and LovB/MlcA have a similar domain architecture and synthesize a common hexaketide precursor, but PSS did not catalyze the [4+2] cycloaddition, whereas LovB/MlcA did.<sup>18</sup> Based on these data, the [4+2] cycloaddition seems to occur after further chain elongation. This suggests two alternative triene intermediates II-3 and II-4 for the cycloaddition in betaenone biosynthesis (Scheme 2 (C); pathway 2 and 3). Further experimental data is required to determine actual biosynthetic pathway.

Most HR-PKSs possess a functionally active ER domain (cis-ER) (Table S2). By contrast, a prominent feature of the *Bet1/3* system is that the cis-ER of Bet1 is inactive and Bet3 participates in the polyketide chain construction as a trans-acting ER (trans-ER). Similar collaborative action of trans-ER is frequently found in PKS-NRPS hybrids.<sup>5, 26</sup> A common feature of Bet1 and PKS-NRPSs is



**Scheme 2.** Proposed mechanism of decalin scaffold formation in (A) solanapyrone A, (B) lovastatin, and (C) betaenone biosynthesis.



**Figure 3.** Lowest energy conformer of **5**. Red and black balls show oxygen and carbon atoms.

that both PKSs produce a linear polyketide chain having a  $\beta$ -ketoacyl group. The exceptional case was reported in the LovB/C system (Table S2), which produces polyketide with a  $\beta$ -hydroxy group.<sup>23</sup> Previous structural analysis of LovC provided sufficient data to propose the catalytic mechanism.<sup>27</sup> A phylogenetic analysis including 8 trans-ERs found in HR-PKS/PKS-NRPS systems and 22 ER domains (cis-ER) of HR-PKS/PKS-NRPSs suggested that ERs could be divided into 3 groups (Figure S7). Trans-ERs, including Bet1 and LovC, form Clade I, while functionally active and inactive cis-ERs are classified into Clade II and Clade III, respectively. This classification is likely general because the uncharacterized HR-PKS system, comprising FSL1 (HR-PKS) and FSL5 (trans-ER) involved in fusarielin biosynthesis,<sup>28</sup> belongs to the same group as Bet1/3 and LovB/C. Multiple sequence alignment revealed a new “fingerprint” region to distinguish functionally active and inactive cis-ERs (Figure S8). In addition, a previously proposed point mutation in the NADPH-binding motif of cis-ERs<sup>29</sup> was also found in that of Accts2, which is classified into Clade II. The inactivation of the ER domain

corresponds to the polyketide structure of ACR-Toxin.<sup>30</sup> Notably, sequence and phylogenetic analyses of ERs revealed that Bet1 and LovB, having a C-terminal reductase domain and a condensation domain, respectively, are classified into the same clade with PKS-NRPS, suggesting an evolution of ancestral PKS-NRPS towards Bet1 and LovB by partial deletion of characteristic domains for NRPS.

In summary, we have identified and characterized the betaenone biosynthetic gene cluster. Through heterologous expression studies, we have established that Bet1 and Bet3 are key enzymes for skeletal construction in betaenone biosynthesis. To our knowledge, this is the first functional characterization of a fungal HR-PKS harboring an R domain, which catalyzes reductive release of the polyketide chain. Based on the chemical reactivity and conformational search of dehydroprobetaenone I, we propose the biosynthetic hypothesis that reductive cleavage of the linear polyketide chain followed by a Diels-Alder reaction gives the *trans*-decalin skeleton. Co-expression of *bet4* and *bet2* with *bet1/3* in *A. oryzae* also revealed subsequent reductive and oxidative modifications in betaenone biosynthesis.

We are grateful to Prof. Masanori Arita of the National Institute of Genetics for meaningful discussions about the phylogenetic analysis of the KS domain of PKS. This work was financially supported by a MEXT research grant on innovation area 22108002 to H. Oikawa.

## Notes and references

<sup>a</sup> Division of Chemistry, Graduate School of Science, Hokkaido University.

<sup>b</sup> Graduate School of Agricultural Science, Tohoku University.

Electronic Supplementary Information (ESI) available: [Experimental procedures, LC-MS data, multiple sequence alignment, phylogenetic analysis, conformational search of **5**, and <sup>1</sup>H and <sup>13</sup>C NMR spectra.]. See DOI: 10.1039/c000000x/

- (a) *Handbook of Secondary Fungal Metabolites, 3-Volume Set* (Eds.: R. J. Cole, B. B. Jarvis, M. A. Schweikert), Elsevier, 2003. (b) *Fungal Metabolites: Volume 2* (Eds.: W. B. Turner), Academic Press Inc, 1982.
- (a) T. T. Dabrah, H. J. Harwood, L. H. Huang, N. D. Jankovich, T. Kaneko, J. –C. Li, S. Lindsey, P. M. Moshier, T. A. Subashi, M. Therrien, P. C. Watts, *J. Antibiot.*, 1997, **50**, 9933. (b) T. T. Dabrah, T. Kaneko, W. Masefski, E. B. Whipple, *J. Am. Chem. Soc.*, 1997, **119**, 1594.
- A. W. Alberts, J. Chen, G. Kuron, V. Hunt, J. Huff, C. Hoffman, J. Rothrock, M. Lopez, H. Joshua, E. Harris, A. Patchett, R. Monaghan, S. Currie, E. Stapley, G. Albers-Schonberg, O. Hensens, J. Hirshfield, K. Hoogsteen, J. Liesch, J. Springer, *Proc. Natl. Acad. Sci. U.S.A.*, 1980, **77**, 3957.
- M. J. Dawson, J. E. Farthing, P. S. Marshall, R. F. Middleton, M. J. O'Neill, A. Shuttleworth, C. Stylli, R. M. Tait, P. M. Taylor, H. G. Wildman, A. D. Buss, D. Langly, M. V. Hayes, *J. Antibiot.*, 1992, **45**, 639.
- Y. H. Chooi and Y. Tang, *J. Org. Chem.*, 2012, **77**, 9933.
- R. J. Cox, T. J. Simpson, in *Comprehensive Natural Products II: Chemistry and Biology, 10 Volume Set*, ed. L. Mander and H. W. Liu, Elsevier, Oxford, 2010, vol. 1, pp. 347-383.
- (a) A. Ichihara, H. Oikawa, K. Hayashi and S. Sakamura, *J. Am. Chem. Soc.*, 1983, **105**, 2907. (b) A. Ichihara, H. Oikawa, M. Hashimoto, S. Sakamura, T. Haraguchi and H. Nagano, *Agric. Biol. Chem.*, 1983, **47**, 2965.
- H. Oikawa, A. Ichihara and S. Sakamura, *J. Chem. Soc., Chem. Commun.*, 1984, 814.
- H. Oikawa, A. Ichihara and S. Sakamura, *J. Chem. Soc., Chem. Commun.*, 1988, 600.
- H. Oikawa, A. Ichihara and S. Sakamura, *J. Chem. Soc., Chem. Commun.*, 1990, 908.
- M. N. Heneghan, A. A. Yakasai, L. M. Halo, Z. Song, A. M. Bailey, T. J. Simpson, R. J. Cox and C. M. Lazarus, *ChemBioChem*, 2010, **11**, 1508.
- R. Fujii, A. Minami, T. Tsukagoshi, N. Sato, T. Sahara, S. Ohgiya, K. Gomi and H. Oikawa, *Biosci. Biotechnol. Biochem.*, 2011, **75**, 1813.
- K. Tagami, C. Liu, A. Minami, M. Noike, T. Isaka, S. Fueki, Y. Shichijo, H. Toshima, K. Gomi and H. Oikawa, *J. Am. Chem. Soc.*, 2013, **135**, 1260.
- Z. Wasil, K. A. K. Pahirulzaman, C. Butts, T. J. Simpson, C. M. Lazarus and R. J. Cox, *Chem. Sci.*, 2013, **4**, 3845.
- K. Tagami, A. Minami, R. Fujii, C. Liu, M. Tanaka, K. Gomi, T. Dairi and H. Oikawa, *ChemBioChem*, 2014, **15**, 2076.
- Y. Matsuda, T. Wakimoto, T. Mori, T. Awakawa, I. Abe, *J. Am. Chem. Soc.*, 2014, **136**, 15326.
- S. Miki, Y. Sato, H. Tabuchi, H. Oikawa, A. Ichihara, S. Sakamura, *J. Chem. Soc., Perkin Trans. 1.*, 1990, 1228.
- K. Kasahara, T. Miyamoto, T. Fujimoto, H. Oguri, T. Tokiwano, H. Oikawa, T. Ebizuka and I. Fujii, *ChemBioChem*, 2010, **11**, 1245.
- I. Fujii, N. Yoshida, S. Shimomaki, H. Oikawa and Y. Ebizuka, *Chem. Biol.*, 2005, **12**, 1301.
- W. Xu, Y. H. Chooi, J. W. Choi, S. Li, J. C. Vederas, N. A. Da Silva and Y. Tang, *Angew. Chem. Int. Ed.*, 2013, **52**, 6472.
- X. Xie, M. J. Meehan, W. Xu, P. C. Dorrestein, Y. Tang, *J. Am. Chem. Soc.*, 2009, **131**, 8388.
- B. Manavalan, S. K. Murugapiran, G. Lee and S. Choi, *BMC. Struct. Biol.*, 2010, **10**, 1.
- S. M. Ma, J. W. H. Li, J. W. Choi, H. Zhou, K. K. M. Lee, V. A. Moorthie, X. Xie, J. T. Kealey, N. A. Da Silva, J. C. Vederas and Y. Tang, *Science*, 2009, **326**, 589.
- (a) H. Oikawa, Y. Suzuki, A. Naya, K. Katayama, A. Ichihara, *J. Am. Chem. Soc.*, 1994, **116**, 3605. (b) H. Oikawa, K. Katayama, Y. Suzuki, A. Ichihara, *J. Chem. Soc., Chem. Commun.*, 1995, 908.
- A. Ichihara, H. Oikawa, M. Hashimoto, S. Sakamura, T. Haraguchi, H. Nagano, *Agric. Biol. Chem.*, 1983, **47**, 2965.
- D. Boettger, C. Hertweck, *ChemBioChem*, 2013, **14**, 28.
- B. D. Ames, C. Nguyen, J. Bruegger, P. Smith, W. Xu, S. Ma, E. Wong, S. Wong, X. Xie, J. W. –H. Li, J. C. Vederas, Y. Tang, S. Tsai, *Proc. Natl. Acad. Sci. U.S.A.*, 2012, **109**, 11144.
- J. L. Sorensen, F. T. Hansen, T. E. Sondergaard, D. Staerk, L. G. Klitgaard, S. Purup, H. Giese and R. J. N. Frandsen, *Environ. Microbiol.*, 2012, **14**, 1159.
- K. Kasahara, I. Fujii, H. Oikawa, Y. Ebizuka, *ChemBioChem*, 2006, **7**, 920.
- Y. Izumi, K. Ohtani, Y. Miyamoto, A. Masunaka, T. Fukumoto, K. Gomi, Y. Tada, K. Ichimura, T. L. Peever, K. Akimitsu, *Mol. Plant. Microbe. Interact.*, 2012, **25**, 1419.